Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aplex Bio AB manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions currently in progress. These actions are being handled by 2 distinct examiners. Furthermore, the prosecution is occurring across 2 distinct art units, indicating that each pending matter is being treated as a separate technical and administrative entity within the patent office. This distribution suggests that the Biotechnology & Pharmaceuticals innovations currently under review are diverse enough to be assigned to different specialized units.
The busiest examiner for Aplex Bio AB is VANN-OJUEKAIYE, KENDRA RAYCHELL, who has 1 busiest examiner pending action. With a total of 2 pending office actions, the workload is split between VANN-OJUEKAIYE, KENDRA RAYCHELL and 1 other distinct examiner. This distribution means that no single examiner dominates the current prosecution landscape. For a practitioner, this requires navigating the specific requirements of 2 distinct art units and the individual tendencies of 2 different examiners. The lack of overlap in examiners or art units suggests that the 2 pending office actions may involve distinct technological applications within the broader field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
| KIM, YOUNG J | 1 | 64.8% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917030 | A METHOD FOR MULTIPLEXED DETECTION OF A PLURALITY OF TARGET BIOMOLECULES | KIM, YOUNG J | 85d overdue |
| 18698435 | NEW NANOPARTICLES FOR USE IN THE DETECTION OF TARGET BIOMOLECULES | VANN-OJUEKAIYE, KENDRA RAYCHELL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917030 | A METHOD FOR MULTIPLEXED DETECTION OF A PLURALITY OF TARGET BIOMOLECULES | KIM, YOUNG J | 85d overdue |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698435 | NEW NANOPARTICLES FOR USE IN THE DETECTION OF TARGET BIOMOLECULES | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §102§103§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 17917030 | A METHOD FOR MULTIPLEXED DETECTION OF A PLURALITY OF TARGET BIOMOLECULES | KIM, YOUNG J | 1681 | §103§112 | Final Rejection | 85d overdue | Pending | Oct 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAplex Bio AB has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kendra Raychell Vann-Ojuekaiye has the most, with 1 of Aplex Bio AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
